{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:21Z","timestamp":1781795781807,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.prro.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T02:25:49Z","timestamp":1543199149000},"page":"e196-e202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors"],"prefix":"10.1016","volume":"9","author":[{"given":"Ky Nam B.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destiny J.","family":"Hause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta M.","family":"Monjazeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung xancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study","volume":"75","author":"Fakiris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMc1203770","article-title":"Central-airway necrosis after stereotactic body-radiation therapy","volume":"366","author":"Corradetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ijrobp.2016.06.035","article-title":"Efficacy and toxicity analysis of NRG oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)","volume":"96","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2015.10.040","article-title":"Primary study endpoint analysis for NRG oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)","volume":"94","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: Atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2010.12.039","article-title":"Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients","volume":"82","author":"Taremi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.prro.2012.10.003","article-title":"Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer","volume":"3","author":"Videtic","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2006.04.013","article-title":"Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I\/II non-small-cell lung cancer","volume":"66","author":"Xia","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/JTO.0b013e31822e71d8","article-title":"Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer","volume":"6","author":"Haasbeek","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2008.08.001","article-title":"Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer","volume":"72","author":"Chang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2016.11.369","article-title":"OA24.05 The Nordic HILUS-Trial - First report of a phase II trial of SBRT of centrally located lung tumors","volume":"12","author":"Lindberg","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2009.25.0753","article-title":"Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904","volume":"28","author":"Bogart","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"dju164","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25","volume":"106","author":"Cheung","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.prro.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"S1835","DOI":"10.1016\/j.jtho.2017.09.525","article-title":"MA 09.02 Ultra-central tumors treated with stereotactic body radiotherapy: A single institutional experience","volume":"12","author":"Yau","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850018303230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850018303230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:22:06Z","timestamp":1761819726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850018303230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1879850018303230"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2018.11.005","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}